VDS has selected the 20 finalists for its international startup competition, among which is Ibions, an online medical service company for nutritional treatment in cancer. The final phase will take place on October 23 and 24 at the City of Arts and Sciences in Valencia. This seventh edition includes some new features, including 10 finalist startups in each of the two categories: Early Stage and Growth Stage.
These startups have been chosen from more than 800 applications submitted this year from 65 different countries. The 20 finalists will have the opportunity to present their projects on the main stage of VDS2024 in front of more than 12,000 professionals and more than 700 investors with assets under management worth more than 200 billion euros who are expected to attend the international technology event. Following these presentations, the two winning startups in the Early Stage and Growth Stage categories will be announced.
A prestigious international jury, composed of Myrthe van der Erve, advisor at Antler; Andy Lurling, co-founder of LUMO Labs; Diederik Stolk, co-founder of Arches Capital; Maxime Paradis, founder and union leader of Paradise Club; and Marcus Hølland Eikeland, program director at Katapult, will select the best startups. These high-level investors and leaders of international corporations were chosen by TNW, a company of The Financial Times and VDS Strategic Partner. They were also responsible for selecting these 20 startups as finalists in the VDS Startup Competition.
The two winning startups will receive several prizes, one of which is an exhibition space for VDS 2025, allowing them to benefit from networking opportunities and promotion of their business at one of the most prominent technology events in Southern Europe.
Another new feature this year is that one of the two winning startups will automatically qualify for the semi-finals of the Startup World Cup organized by Pegasus Tech Ventures, the world's largest startup competition offering a $1 million investment prize to the winner.
A model based on the latest scientific advances and associated with psychological support and physical exercise
The healthcare startup, part of the High Technology Incubator in Sustainable Food, AgrotecUV (UV-FPCUV), is working on the creation of a new platform to effectively offer nutritional services to cancer patients. In addition, among its future plans is the implementation of its solution in hospitals as part of the portfolio of medical services, and later expand its solution in hospitals in Latin America.
Since its inception Ibions works with classic online consultations, which after an in-person assessment, raises an initial work plan of three months and eight sessions. However, from now on, Ibions will introduce a new platform where patients who wish to do so can learn how to manage their nutrition in a self-taught way through a self-guide with videos and sessions with the company to resolve any doubts that may arise. With it they will develop pilot trials within the health system together with oncologists and demonstrate that therapeutic nutrition is key after the diagnosis of cancer.
Collaboration between FPCUV and VDS 2024
As in 2023, the University of Valencia Science Park Foundation is once again committed to this activity within the framework of the Innovation Transfer Exhibition Program (PETI) with the support in 2024 of the Regional Ministry of Innovation, Industry, Trade and Tourism of the Valencian Government with the aim of disseminating and publicizing applied innovation generated by the PCUV business ecosystem to the widest possible audience in society, with special emphasis on specific audiences, Commerce and Tourism of the Valencian Government with the aim of disseminating and spreading the applied innovation generated by the entrepreneurial ecosystem of the PCUV to the widest possible range of society, with special emphasis on specific audiences of investors, other innovative companies and startups, corporations and large companies, media, among others, hoping that this program will be of interest and useful to you.
With the support of: